| NH2-MIL-125 |
2-Aminoterephthalic acid |
— |
E. coli
|
E. coli
|
33
|
|
S. aureus
|
S. aureus
|
| — |
|
| Zr-MOF and Ti-MOF |
2-Aminoterephthalic acid and silane surface modification |
Animal study and plasma detection via DPPH˙ |
— |
— |
38
|
| Zn-PDA |
2,6-Pyridine dicarboxylic acid |
— |
— |
E. coli
|
51
|
| ZnO@ZIF-8 |
2-Methylimidazole |
— |
— |
E. coli and S. aureus
|
66
|
| Zn-MOF |
4,4′-Bipyridine |
— |
— |
S. epidermidis, E. coli
|
67
|
| Calcium gallate MOFs (MIL-155 and MIL-156) |
Gallic acid |
Dichlorofluorescein diacetate (125 and 250 mg mL−1) |
— |
— |
68
|
| AgTAZ, ZIF-67, and Co-SIM-1 |
1,2,4-Triazole and 2-methylimidazole |
— |
— |
E. coli CECT-4102 Pseudomonas putida CECT-4584, and Saccharomyces cerevisiae CECT-1170 |
69
|
| Co-MOF@graphene oxide |
1,4-Benzenedicarboxylic acid |
Via DPPH˙ |
|
E. coli ATCC-25922 S. aureus ATCC-33591 |
70
|
| Zn-MOF and Co-MOF |
4,6-Diamino-2-pyrimidinethiol |
DPPH˙ (0.2676 and 0.2197 mg mL−1) |
Against S. aureus ATCC 6538 (0.01337 and 0.01269 mg mL−1) |
S. aureus (clinic) S. aureus ATCC 6538 P. aeruginosa (clinic) P. aeruginosa ATCC 9027 |
This work |
